<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113127</article-id><article-id pub-id-type="publisher-id">ACM-40828</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_14008782.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  急性心肌梗死合并低T3综合征发生机制的研究进展
  Research Progress on Pathogenesis and Harm of Acute Myocardial Infarction Complicated with Low T3 Syndrome
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>薛</surname><given-names>万腾</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吕</surname><given-names>志慧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>营忠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>889</fpage><lpage>894</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    急性心肌梗死目前是缺血性心脏病的主要病因及死亡原因，急性心肌梗死将导致甲状腺功能的急性改变，甲状腺激素在心脏血管生理病理过程中起着重要作用，急性心肌梗死时出现低T3综合征，低T3综合征进一步加重心肌损害，本文就其发生机制及危害性的研究进展做一综述。
    Acute myocardial infarction is the leading cause of ischemic heart disease and cause of death. Acute myocardial infarction will lead to acute alterations in thyroid function. Thyroid hormone in cardiac blood vessels plays an important role in physiological and pathological process. Low T3 syndrome occurs in acute myocardial infarction, and further aggravates myocardial damage. This paper summarizes the research progress of its occurrence mechanism and harm. 
  
 
</p></abstract><kwd-group><kwd>急性心肌梗死，低T3综合征, Acute Myocardial Infarction</kwd><kwd> Low T3 Syndrome</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>急性心肌梗死目前是缺血性心脏病的主要病因及死亡原因，急性心肌梗死将导致甲状腺功能的急性改变，甲状腺激素在心脏血管生理病理过程中起着重要作用，急性心肌梗死时出现低T3综合征，低T3综合征进一步加重心肌损害，本文就其发生机制及危害性的研究进展做一综述。</p></sec><sec id="s2"><title>关键词</title><p>急性心肌梗死，低T3综合征</p></sec><sec id="s3"><title>Research Progress on Pathogenesis and Harm of Acute Myocardial Infarction Complicated with Low T3 Syndrome<sup> </sup></title><p>Wanteng Xue, Zhihui Lv, Yingzhong Wang<sup>*</sup></p><p>Yan’an University Affiliated Hospital, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/10-1572026x4_hanspub.png" /></p><p>Received: Feb. 8<sup>th</sup>, 2021; accepted: Feb. 28<sup>th</sup>, 2021; published: Mar. 9<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/10-1572026x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Acute myocardial infarction is the leading cause of ischemic heart disease and cause of death. Acute myocardial infarction will lead to acute alterations in thyroid function. Thyroid hormone in cardiac blood vessels plays an important role in physiological and pathological process. Low T3 syndrome occurs in acute myocardial infarction, and further aggravates myocardial damage. This paper summarizes the research progress of its occurrence mechanism and harm.</p><p>Keywords:Acute Myocardial Infarction, Low T3 Syndrome</p><disp-formula id="hanspub.40828-formula6"><graphic xlink:href="//html.hanspub.org/file/10-1572026x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/10-1572026x8_hanspub.png" /> <img src="//html.hanspub.org/file/10-1572026x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>急性心肌梗死(Acute myocardial infarction, AMI)，是由于冠状动脉严重阻塞，导致心肌细胞供血、供氧不足，发生不可逆性坏死，是一类临床危重症疾病，具有高致死率、致残率等特点，对人民的生命财产造成了巨大的损伤。三碘甲状腺原氨酸(T3)和甲状腺素(T4)是甲状腺激素的主要存在形式，其在生命活动中起到重要作用，心脏是其最重要的靶器官之一。血清游离三碘甲状腺原氨酸(FT3)通过基因组和非基因组两种途径，调节多种蛋白质的表达，一方面T3与自身受体结合，介导心肌细胞表示收缩蛋白，另一方面激活肌球蛋白重链表达而影响肌质网Ca<sup>2+</sup>-ATP酶的表达，从而影响心肌细胞的表型和形态 [<xref ref-type="bibr" rid="hanspub.40828-ref1">1</xref>]。低T3综合征又称非甲状腺病态综合征(Non-thyroid pathological syndrome, NTIS)，主要表现为游离三碘甲状腺原氨酸(FT3)水平降低、游离甲状腺素(FT4)及促甲状腺激素(TSH)水平处于参考范围或降低，在临床方面，NTIS可见于多种严重疾病(如脑外伤、严重感染、烧伤、心力衰竭、急性心肌梗死、急性脑梗死)并对于评价病情严重程度和预后均具有重要价值 [<xref ref-type="bibr" rid="hanspub.40828-ref2">2</xref>]。临床研究发现，约18.6%的急性心肌梗死的患者存在低T3综合征，且合并低T3综合征的患者冠脉病变程度越重，院内或院外不良事件的发生率越高，患者预后情况差的同时发现低T3综合征是急性心肌梗死冠脉病变严重程度及预后的独立危险因素之一 [<xref ref-type="bibr" rid="hanspub.40828-ref3">3</xref>]；国外的一项前瞻性横断面研究观察心脏重症监护室急性心肌梗死患者400例，分析后发现大约10.2%的危重患者合并低T3综合征，且这部分病人预后差，与T3水平降低明显相关 [<xref ref-type="bibr" rid="hanspub.40828-ref4">4</xref>]。本文就急性心肌梗死合并低T3综合征发生机制及危害的研究进展进行综述。</p></sec><sec id="s6"><title>2. AMI时低T3综合征的发生机制</title><p>目前急性心肌梗死后合并低T3综合征的发病机制尚不明确，目前研究认为可能与以下几方面相关：1) 下丘脑–垂体–甲状腺轴神经内分泌功能紊乱；2) 5-脱碘酶活性降低；3) 甲状腺激素结合球蛋白水平降低；4) 细胞因子介导的氧化应激；5) 硒缺乏等方面相关。</p><sec id="s6_1"><title>2.1. 下丘脑–垂体–甲状腺轴神经内分泌功能紊乱</title><p>应激状态下或机体被严重打击情况下会产生一系列神经–内分泌的改变，急性心肌梗死后主要表现为下丘脑–垂体–甲状腺轴功能的絮乱，糖皮质激素、儿茶酚胺、细胞因子的大量释放增加甲状腺细胞对TSH细胞的反应阈值，从而使循环中血清T3、T4水平降低。肿瘤坏死因子-α (Tumor necrosis factor-alpha TNF-α)是一种由刺激的巨噬细胞分泌的多肽，在炎症性和肿瘤性疾病中介导代谢紊乱。Pang [<xref ref-type="bibr" rid="hanspub.40828-ref5">5</xref>] 等研究发现TNF-α通过抑制大鼠甲状腺细胞摄取碘125，并在多个水平上作用于下丘脑–垂体–甲状腺轴，促甲状腺激素信使蛋白质的合成，进一步降低TSH的生物活性，TNF-α是导致NTIS改变的介质之一。部分研究指出下丘脑–垂体–甲状腺轴功能的紊乱，能增加重大疾病的病死率和致残率，考虑甲状腺激素的功能细胞因子及应激激素的释放导致下丘脑–垂体–甲状腺轴功能絮乱等因素相关 [<xref ref-type="bibr" rid="hanspub.40828-ref6">6</xref>]。</p></sec><sec id="s6_2"><title>2.2. 5-脱碘酶活性降低</title><p>一般认为甲状腺素脱碘酶产生的氧化应激干扰，可能对甲状腺素活性造成增强或减弱作用。碘甲状腺原氨酸去碘酶是催化甲状腺激素碘去除的酶包括I型和II型脱碘酶(分别为D1和D2)促进甲状腺素T4转化为T3活性，而III型酶(D3)则使T4和T3失活。D3在甲状腺激素灭活过程中起最主要的作用。氧化还原状态的失衡导致NTIS中D3的功能障碍 [<xref ref-type="bibr" rid="hanspub.40828-ref7">7</xref>]。急性心肌梗死时心肌严重缺血、缺氧导致心肌细胞坏死机体处于急性应激状态，糖皮质激素、儿茶酚胺和白介素6 (IL-6)等合成、分泌、释放增多，氧化应激的失衡导致外周组织中T4向T3转变过程减少，血清T3浓度下降，从而导致低T3综合征的发生，目前该机制被认为是NTIS的主要发生机制 [<xref ref-type="bibr" rid="hanspub.40828-ref8">8</xref>]。</p></sec><sec id="s6_3"><title>2.3. 甲状腺激素结合球蛋白水平降低</title><p>血清中甲状腺激素T3、T4主要与肝脏合成的血清白蛋白结合而发挥作用，部分血清甲状腺激素以游离状态存在，二者在一定条件下相互转换，动态平衡，维持机体活动的需求。Warner等将急性应激状态疾病模型的小鼠，敲除其D1、D2基因，发现肝脏细胞D1活性的下降晚于血清T3、T4的下降，间接说明急性应激状态下血清甲状腺结合球蛋白结合能力下降；另一方面血清白蛋白最为重要转运载体，可结合多种物质，急性心肌梗死时，释放大量细胞因子、糖皮质激素、脂肪酸，均可与血清白蛋白竞争性结合，尤其脂肪酸对T3、T4的竞争性最大，其可代替甲状腺激素与甲状腺结合球蛋白结合，急性心肌梗死合并低T3综合征时，肝脏合成血清白蛋白能力进一步下降，从而降低血清甲状腺激素水平 [<xref ref-type="bibr" rid="hanspub.40828-ref9">9</xref>]。</p></sec><sec id="s6_4"><title>2.4. 细胞因子介导的氧化应激</title><p>白介素6 (IL-6)和肿瘤坏死因子(TNF-α)等细胞因子的释放增加，是急性期急性心肌梗死合并低T3综合征的标志之一。神经内分泌通路是维持机体免疫系统稳定的重要途径，其主要通过自分泌和旁分泌两种途径得以实现，研究发现细胞因子是内分泌通路的重要信号分子，参与炎症反应的发生。急性心肌梗死等应激状态下大量释放IL-6等炎症因子，一方面可以降低D1、D2的活性，减少血清中甲状激素T4向T3的转变；另一方面增加对T3、T4的灭活作用 [<xref ref-type="bibr" rid="hanspub.40828-ref10">10</xref>]。研究者测定IL-6对内源性辅因子介导的刺激效应和二硫苏糖醇(DTT刺激)在人类细胞超声脱碘酶活性研究发现无论是否存在IL-6和亚硒酸盐，内源性脱碘酶1型(D1)、2型(D2)或3型(D3) (尤其是HEPG2，MSTO和MCF-7细胞)，可还原生理条件下底物和辅助因子的脱碘酶工作过程，所以该细胞经常被用于完整细胞模型。唑来膦酸(Zoledronic acid, ZA)诱导与血清细胞因子升高相关的急性期反应，这可能改变三种碘甲状腺原氨酸去碘酶活性。因此，研究者研究了急性期甲状腺功能的变化，发现CRP、IL-6和TNF-α水平升高的同时，FT3水平下降，并在第2天达到最低点，所有甲状腺功能变化在第3天恢复到基线水平，但细胞因子水平仍然较高，但低于第2天。甲状腺激素的变化可以部分解释为TNF-α的增加。ZA引起短期甲状腺激素的变化，这是NTIS的特征，并与TNF-α和IL-6的增加相关，IL-6诱导活性氧和碳酰基含量增加，活性氧通过诱导D1和D2降低T4向T3的转变，同时增加D3催化降解血清甲状腺激素T3。在急性心肌梗死等急性应激状态下，白介素6 (IL-6)和肿瘤坏死因子(TNF-α)等细胞因子增加，但对改变甲状腺激素水平的因子的作用的相关研究仍较少。研究发现IL-6一方面抑制D1和D2介导的T3的生成，另一反面刺激内源性D3对T3的灭活作用。这些实验研究说明细胞因子IL-6、TNF-α在急性心肌梗死中激活炎症反应增加活性氧的释放，减少血清甲状腺激素T3，表明细胞因子参与NTIS的过程 [<xref ref-type="bibr" rid="hanspub.40828-ref11">11</xref>]。Lehnen等研究通过两组具有相似的梗死区域的模型雄性大鼠分别接受N-乙酰半胱氨酸(NAC)和安慰剂治疗，测量心肌梗死后10天及28天血清T3水平，结果安慰剂组血清T3降低，NAC组没变化且较安慰剂组有较高的射血分数。心肌梗死后10天和28天，安慰剂组梗死周围组织样品中的3型碘化甲腺氨酸脱碘酶染色增强，但NAC治疗组没有。提示急性心肌梗死抗氧化应激治疗，可减少合并低T3综合征的风险 [<xref ref-type="bibr" rid="hanspub.40828-ref12">12</xref>]。Vidart等一项随机多中心临床研究提示氧化应激是周围甲状腺激素代谢紊乱的一个原因。67名急性心肌梗死合并NTIS患者在48小时内随机接受N-乙酰半胱氨酸(N-acetylcysteine)或安慰剂，结果显示NAC可防止急性心肌梗死急性期常见的甲状腺激素浓度紊乱，这表明危重症患者氧化应激状态下由于脱碘酶功能的抑制，降低了血清T3与T4的比值，降低了D1和D2介导的T4向T3转化同时增加D3介导的T3失活，参与NTIS的病理生理过程 [<xref ref-type="bibr" rid="hanspub.40828-ref13">13</xref>]。综上所述细胞因子IL-6、TNF-α等细胞因子的释放介导的氧化应激反应是急性心肌梗死合并低T3综合征的重要发生机制。IL-6、TNF-α等细胞因子仅通过减少TSH对甲状腺激素细胞的作用，并不对甲状腺细胞造成损伤的方式，减少血清中甲状腺激素T3的含量。</p></sec><sec id="s6_5"><title>2.5. 硒缺乏</title><p>硒是维持生命活动的一种重要微量元素，在人体中主要存在于D1和谷胱甘肽过氧化酶(GPX)，主要通过硫氧还原蛋白还原酶(TRX)和谷胱甘肽过氧化物酶(GPX)发挥抗氧化作用，当体内硒缺乏时会降低甲状腺中谷胱甘肽过氧化酶(GPX)和硫氧还原蛋白还原酶(TRX的活性)降低甲状腺细胞抗氧化的能力，然而在甲状腺激素T4活化的过程中需要通过氧自由基通路；血清微量元素硒不足时血清D3的活性将进一步降低，从而大大降低血清T3的合成。Liu等对53例尿毒症血液透析患者进行的一项研究中发现血透组患者血清硒水平与白蛋白、HDL-C、TT3、FT3等呈显著正相关，提示在急性重症疾病状态下，微量元素硒的缺乏更易发生低T3综合征，血清硒水平与FT3水平呈显著正相关，高度说明急性应激状态下，尤其是急性心肌梗死等疾病下硒缺乏可能参与低T3综合征的发生 [<xref ref-type="bibr" rid="hanspub.40828-ref14">14</xref>]。</p></sec></sec><sec id="s7"><title>3. 低T3综合征对急性心肌梗死的危害</title><p>急性心肌梗死合并低T3综合征临床并不少见，常与病人不良预后及并发症相关，目前主要认为可能与以下几种并发症相关。</p><sec id="s7_1"><title>3.1. 诱发心力衰竭</title><p>急性心肌梗死后心竭是最常见的并发症之一，往往预示着患者预后严重不良，以血流动力学不稳定及心室重构为主要表现。急性心肌梗死后合并低T3综合征，一方面抑制T4向T3的转化，游离T4转化为无活性的反三碘甲状腺原氨酸(rT3) ，较低的T3水平导致细胞内肌质网Ca<sup>2+</sup>-ATP酶、Na<sup>+</sup>-K + -ATP酶活性降低，发挥负性肌力作用，减少心排出血量，减慢心率。另一方面低T3水平可改变肾素–血管紧张素–醛固酮及肾上腺素能活性，影响血液动力学增加心室前负荷，促进心室重构。Pinellim等研究发现部分低T3综合征患者NT-Pro BNP升高，临床中NT-Pro BNP浓度升高往往预警急性心肌梗死患者合并心衰，说明NT-Pro BNP与T3存在关联 [<xref ref-type="bibr" rid="hanspub.40828-ref15">15</xref>]。Okayamad等研究发现，急性心肌梗死伴急性心衰患者，T3水平与院内死亡率独立相关，且1年内MACE事件发生率明显高于T3正常者组 [<xref ref-type="bibr" rid="hanspub.40828-ref16">16</xref>]。多项研究表明，低T3水平的程度与心衰患者心功能分层高度相关，且T3水平是急性心肌梗死合并心衰MACE事件发生的独立危险因素 [<xref ref-type="bibr" rid="hanspub.40828-ref17">17</xref>]。</p></sec><sec id="s7_2"><title>3.2. 诱发心率失常</title><p>急性心肌梗死后心脏结构变化，易发生心电功能的絮乱。研究发现，T3水平降低是冠心病并发心房颤动的独立危险因素。Dietrich等在一项17例心脏术后房颤(Postoperative atrial fibrillation)患者的研究中发现其中7例表现为非甲状腺疾病综合征。POAF患者血清FT3浓度明显降低，但仍在参考范围内。多变量logistic回归分析显示FT3、总心房传导时间、左房容积指数和是POAF的独立预测因子 [<xref ref-type="bibr" rid="hanspub.40828-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40828-ref19">19</xref>]。</p></sec></sec><sec id="s8"><title>4. 甲状腺激素替代治疗</title><p>机体各个器官对甲状腺激素的敏感程度不一，且甲状腺激素与疾病的预后密切相关，因此对于合并T3综合征的患者是否接受甲状腺激素代替治疗，目前仍存在较大争议。Pingitore等的一项随机安慰剂对照研究给予缺血性心脏病合并低T3综合征患者小剂量甲状腺激素代替治疗，可显著改善患者症状 [<xref ref-type="bibr" rid="hanspub.40828-ref20">20</xref>]。一项对于686例行经皮冠状动脉介入治疗后合并低T3综合征患者予以甲状腺激素替代治疗的研究发现，甲状腺激素替代治疗，可明显减少MACE事件的发生 [<xref ref-type="bibr" rid="hanspub.40828-ref21">21</xref>]。也有动物实验提示，给予急性心肌梗死动物生理剂量T3可有效预防心室重构，但过剂量的甲状腺激素补充可引起心肌耗氧量增大诱发心率失常。目前关于甲状腺激素替代治疗的使用时机、剂量、使用时间尚无统一标准，仍需大量实验进行探索。</p></sec><sec id="s9"><title>5. 小结与展望</title><p>综上所述，急性心肌梗死合并低T3综合征的发病机制由多种机制参与，研究表明低T3综合征在评估急性心肌梗死患者的病变严重程度及预后具有重要意义。目前对于是否补充甲状腺激素尚无统一观点，随着更多新型甲状腺激素的研发和临床试验及基础机制研究的开展，相信未来会为临床治疗提供更合理、更科学的指导。</p></sec><sec id="s10"><title>文章引用</title><p>薛万腾,吕志慧,王营忠. 急性心肌梗死合并低T3综合征发生机制的研究进展Research Progress on Pathogenesis and Harm of Acute Myocardial Infarction Complicated with Low T3 Syndrome[J]. 临床医学进展, 2021, 11(03): 889-894. https://doi.org/10.12677/ACM.2021.113127</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40828-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Galli, E., Pingitore, A. and Iervasi, G. (2010) The Role of Thyroid Hormone in the Pathophysiology of Heart Failure: Clinical Evidence. Heart Failure Reviews, 15, 155-169. &lt;br&gt;https://doi.org/10.1007/s10741-008-9126-6</mixed-citation></ref><ref id="hanspub.40828-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Adomas, B., Timothy, S. and Laws, E.R. (2016) Low Tri-Iodothyronine Syndrome in Neurosurgical Patients: A Systematic Review of Literature. World Neurosurgery, 95, 197-207. &lt;br&gt;https://doi.org/10.1016/j.wneu.2016.07.035</mixed-citation></ref><ref id="hanspub.40828-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Coceani, M. (2013) Heart Disease in Patients with Thyroid Dysfunction: Hyperthyroidism, Hypothyroidism and Beyond. Anadolu Kardiyoloji Dergisi, 13, 62-66.</mixed-citation></ref><ref id="hanspub.40828-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Abdulaziz, Q.F. (2015) Thyroid Hormone Profile in Patients with Acute Coronary Syndrome. Iranian Red Crescent Medical Journal, 17, e26919. &lt;br&gt;https://doi.org/10.5812/ircmj.26919v2</mixed-citation></ref><ref id="hanspub.40828-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Pang, X.P., Hershman, J.M., Mirell, C.J., et al. (1989) Impairment of Hypothalamic-Pituitary-Thyroid Function in Rats Treated with Human Recombinant Tumor Necrosis Factor-Alpha (Cachectin). Endocrinology, 125, 76-84.  
&lt;br&gt;https://doi.org/10.1210/endo-125-1-76</mixed-citation></ref><ref id="hanspub.40828-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Müller, J. and Heuer, H. (2012) Understanding the Hypothalamus-Pituitary-Thyroid Axis in mct8 Deficiency. European Thyroid Journal, 1, 72-79. &lt;br&gt;https://doi.org/10.1159/000339474</mixed-citation></ref><ref id="hanspub.40828-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Lehnen, T.E., Marschner, R., Dias, F., Maia, A.L. and Wajner, S.M. (2020) Oxidative Remote Induction of Type 3 Deiodinase Impacts Nonthyroidal Illness Syndrome. Journal of Endocrinology, 246, 237-246.  
&lt;br&gt;https://doi.org/10.1530/JOE-19-0574</mixed-citation></ref><ref id="hanspub.40828-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">胡圆圆, 叶山东. 低T3综合征研究进展[J]. 临床与病理杂志, 2015, 35(12): 2160-2164.</mixed-citation></ref><ref id="hanspub.40828-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wajner, S.M., Goemann, I.M., Bueno, A.L., et al. (2011) IL-6 Promotes Nonthyroidal Illness Syndrome by Blocking Thyroxine Activation While Promoting Thyroid Hormone Inactivation in Human Cells. The Journal of Clinical Investigation, 121, 1834-1845. &lt;br&gt;https://doi.org/10.1172/JCI44678</mixed-citation></ref><ref id="hanspub.40828-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Qin, S.L., He, Q., Hu, L., He, C.Y., Gao, L.C., Young, C.A., Chen, J., Jiang, C.F., Luo, X.F., Zhou, Y., Sheng, X., Li, Z.H., Chen, M.L. and Xu, G. (2018) The Relationship between Inflammatory Factors, Oxidative Stress and DIO-1 Concentration in Patients with Chronic Renal Failure Accompanied with or without Euthyroid Sick Syndrome. Journal of International Medical Research, 46, 4061-4070. &lt;br&gt;https://doi.org/10.1177/0300060518778190</mixed-citation></ref><ref id="hanspub.40828-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Karga, H., Giagourta, I., Papaioannou, G., et al. (2011) Transient Changes in Thyroid Functions Tests after Zoledronic Acid Infusion. Endocrine Journal, 58, 969-977. &lt;br&gt;https://doi.org/10.1507/endocrj.EJ11-0039</mixed-citation></ref><ref id="hanspub.40828-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lehnen, T.E., Santos, M.V., Lima, A., et al. (2017) N-Acetylcysteine Prevents Low T3 Syndrome and Attenuates Cardiac Dysfunction in a Male Rat Model of Myocardial Infarction. Endocrinology, 158, 1502-1510.  
&lt;br&gt;https://doi.org/10.1210/en.2016-1586</mixed-citation></ref><ref id="hanspub.40828-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Vidart, J., Wajner, S.M., Leite, R.S., et al. (2014) N-Acetylcysteine Administration Prevents Nonthyroidal Illness Syndrome in Patients with Acute Myocardial Infarction: A Randomized Clinical Trial. The Journal of Clinical Endocrinology &amp; Metabolism, 99, 4537-4545. &lt;br&gt;https://doi.org/10.1210/jc.2014-2192</mixed-citation></ref><ref id="hanspub.40828-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Liu, M.-L., Xu, G., Huang, Z.-Y., et al. (2011) Euthyroid Sick Syndrome and Nutritional Status Are Correlated with Hyposelenemia in Hemodialysis Patients. The International Journal of Artificial Organs, 34, 577-583.  
&lt;br&gt;https://doi.org/10.5301/IJAO.2011.8474</mixed-citation></ref><ref id="hanspub.40828-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Pinelli, M., Bindi, M., Cassetti, G., et al. (2007) Relationship between Low T3 Syndrome and NT-proBNP Levels in Non-Cardiac Patients. Acta Cardiologica, 62, 19-24. &lt;br&gt;https://doi.org/10.2143/AC.62.1.2019366</mixed-citation></ref><ref id="hanspub.40828-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Okayama, D., Minami, Y., Kataoka, S., et al. (2015) Thyroid Function on Admission and Outcome in Patients Hospitalized for Acute Decompensated Heart Failure. Journal of Cardiology, 66, 205-211.  
&lt;br&gt;https://doi.org/10.1016/j.jjcc.2015.04.006</mixed-citation></ref><ref id="hanspub.40828-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Chuang, C.-P., Jong, Y.-S., Wu, C.-Y., et al. (2014) Impact of Triiodothyronine and N-Terminal Pro-B-Type Natriuretic Peptide on the Long-Term Survival of Critically Ill Patients with Acute Heart Failure. American Journal of Cardiology, 113, 845-850. &lt;br&gt;https://doi.org/10.1016/j.amjcard.2013.11.039</mixed-citation></ref><ref id="hanspub.40828-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Cerillo, A.G., Storti, S., Kallushi, E., et al. (2014) The Low Triiodothyronine Syndrome: A Strong Predictor of Low Cardiac Output and Death in Patients Undergoing Coronary Artery Bypass Grafting. The Annals of Thoracic Surgery, 97, 2089-2095. &lt;br&gt;https://doi.org/10.1016/j.athoracsur.2014.01.049</mixed-citation></ref><ref id="hanspub.40828-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Dietrich, J.W., Müller, P., Schiedat, F., et al. (2015) Nonthyroidal Illness Syndrome in Cardiac Illness Involves Elevated Concentrations of 3,5-Diiodothyronine and Correlates with Atrial Remodeling. European Thyroid Journal, 4, 129-137. &lt;br&gt;https://doi.org/10.1159/000381543</mixed-citation></ref><ref id="hanspub.40828-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Pingitore, A., Galli, E., Barison, A., et al. (2008) Acute Effects of Triiodothyronine (T3) Replacement Therapy in Patients with Chronic Heart Failure and Low-T3 Syndrome: A Randomized, Placebo-Controlled Study. The Journal of Clinical Endocrinology &amp; Metabolism, 93, 1351-1358. &lt;br&gt;https://doi.org/10.1210/jc.2007-2210</mixed-citation></ref><ref id="hanspub.40828-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, M., Sara, J.D.S., Matsuzawa, Y., et al. (2016) Clinical Outcomes of Patients with Hypothyroidism Undergoing Percutaneous Coronary Intervention. European Heart Journal, 37, 2055-2065.  
&lt;br&gt;https://doi.org/10.1093/eurheartj/ehv737</mixed-citation></ref></ref-list></back></article>